S Biomedics is showing an upward trend, buoyed by positive evaluations from the securities industry regarding the clinical performance of its Parkinson's disease cell therapy.

On the 16th, S Biomedics is trading at 26,600 won, up 300 won (1.14%) from the previous trading day.

On this day, DS Investment Securities published a new research report on S Biomedics, presenting an investment opinion of 'BUY' and a target price of 65,000 won. This analysis suggests approximately 147.1% additional upside potential based on the previous day's closing price.

24-Month Results from TED-A9 Phase 1/2a Clinical Trial Revealed

According to the report, S Biomedics disclosed the 24-month follow-up results of the Phase 1/2a clinical trial for its Parkinson's disease cell therapy 'TED-A9' on the 12th. The company stated that the high-dose group showed an improvement of approximately 18.5 points at the 24-month mark in MDS-UPDRS Part III (OFF), a motor function evaluation metric.

DS Investment Securities evaluated that, based on these results, a tendency was observed where the therapeutic effect gradually strengthened over time. In particular, the firm noted the confirmation of efficacy signals even in long-term follow-up, predicting that future clinical development progress will be a key variable for the company's valuation.

The market views these results as a meaningful case demonstrating the potential of cell therapy-based technology for treating Parkinson's disease.

Continuous Stem Cell and Regenerative Medicine R&D... Ongoing Interest

S Biomedics is conducting research and development primarily in the fields of stem cells and regenerative medicine, and investor interest continues as its major pipelines make clinical progress.

However, the investment industry advises that for clinical-stage biotech companies, stock price volatility may expand depending on R&D outcomes, regulatory procedures, and additional clinical results, making it necessary to continuously monitor related schedules and outcomes.

[※ This article was written with the assistance of AI. Investment decisions are the responsibility of the investor, and the information contained in this article may change depending on market conditions.]